Partner, European Patent Attorney, Patent attorney litigator
Nick is a member of our life sciences patent team and has experience in the pharmaceutical, biotechnology, agricultural sciences and Cleantech sectors.
Nick’s expertise includes:
Nick has been “recommended” for patent prosecution in “IAM Patent 1000: The World’s Leading Patent Practitioners” 2012, 2013 ,2014 and 2016 editions. In 2014, IAM said “Nick Sutcliffe drafts patents and conducts due diligence projects while advising on global filing strategies”. 2016 guide recommends Nick for his “fortes in biotechnology, agricultural sciences and cleantech“.
Nick is individually recognised in Managing Intellectual Property’s IP Stars 2014 -2016 as an “IP Star” and in the LMG (Legal Media Group) Life Sciences Europe 2014 Guide as a “Life Science Star”.
He is named as a “key contact in the life sciences group” in the Legal 500 (2015).
Nick deals mainly with drafting and prosecution work and also advises on filing strategies and world-wide portfolio management. Nick is also experienced in defensive and offensive European oppositions and due diligence work. His clients include British universities, charities, SMEs and direct foreign clients.
Nick has a BSc in biochemistry from the University of Bristol and a PhD in biochemistry from the University of Leicester. His PhD project concerned the cloning of high expression regulatory elements from myeloma cell lines. Before joining Mewburn Ellis, Nick spent 3 years as a research scientist in industry working on a range of projects in molecular biology and protein engineering, in particular bacterial gene amplification and recombinant luciferase expression.
Nick joined Mewburn Ellis LLP in 1997, qualifying as a Chartered Patent Attorney and a European Patent Attorney in 2001. He joined the partnership in 2003. Nick was awarded a Higher Courts Litigation Certificate in 2015 allowing him to conduct intellectual property litigation in all relevant courts, including the Patents Court (High Court), the Intellectual Property Enterprise Court and on appeal from the Patents Court or the Intellectual Property Enterprise Court.